| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.054 | 0.2 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.2 |